While allergen immunotherapy (AIT) for IgE-mediated diseases holds curative potential, the considerable heterogeneity in clinical outcomes may relate to the complex mechanisms of tolerance. The regulation of humoral immunity by AIT contributes to the suppression of allergic responses. Recent findings have revealed novel roles for IgA and IgG antibodies in the induction of tolerance. These mechanisms synergize with their ability to block allergen-IgE binding and mediate inhibitory signaling of effector cells of the allergic response. In addition, the regulatory activity of B cells in AIT extends beyond IL-10 secretion and induction of IgG 4 . Here, we review the evolution of the B cell response during AIT with special emphasis on the novel protective mechanisms entailing humoral immunity.
Introduction
Allergic diseases are a growing health, economic and social concern worldwide [1] . Currently, allergen immunotherapy (AIT) is the only treatment for allergic diseases with potential curative effects that is allergen-specific. However, it still faces considerable drawbacks in terms of efficacy, safety, long-term duration, and patient adherence [2] . Since the clinical manifestations of allergic diseases are largely mediated by IgE [3] , a proper regulation of the B cell response in AIT seems critical to reach allergen tolerance. Interestingly, a boost of allergenspecific IgE in serum is characteristic of the B cell response at the beginning of AIT and seems to occur regardless of the route (i.e., oral, sublingual, epicutaneous) and the type of allergen (foods, pollens, etc.) [4] [5] [6] [7] [8] . The increase of allergenspecific IgE may be due to memory responses triggered by allergen exposure [9] . Although IgE production is invigorated during the initial stages of AIT, serum levels of allergenspecific IgE tend to decline over time despite regular and increasing doses of allergen exposure [8, 10] . This infers that protective mechanisms that entail the B cell compartment are articulated during AIT.
B Cells as Producers of Antibodies in AIT

IgE Modulation in AIT
The early boost in allergen-specific IgE that occurs in AIT has been perplexing. Universally across most forms of AIT, post-AIT levels of IgE are similar or lower than at baseline [10] [11] [12] [13] [14] [15] . Some mechanistic insight was provided by a recent study in mice which reported that lifelong memory responses perpetuate IgE immunity and anaphylaxis in food allergy [16••] . Mice intragastrically sensitized to peanut and cholera toxin were rested for up to 15 months post-sensitization and developed IgE responses on oral allergen exposure under non-sensitizing conditions. Adoptive transfer experiments of splenocytes from allergic mice to immunodeficient hosts and ex vivo cultures indicated that this process required CD4 T cells and IL-4 production [16••] . Interestingly, allergen-specific Th2 memory responses have been detected in patients with peanut allergy after 12 to 24 months of oral AIT [17•] and have been proposed to be a cause of unsuccessful AIT. Therefore, the boost of allergen-specific IgE in serum at the beginning of AIT is likely due to IgE-generating secondary responses.
The nature of the IgE memory B cell reservoir in allergy is enigmatic as the cytometric identification of these cells has demonstrated to be technically challenging. Additionally, these cells are extremely rare or non-existent in mice [18] . The discovery of sequential class-switching to IgE from other isotypes, such as IgG, in allergy [19] has provided a possible mechanism by which allergen-specific IgE pathways may be reactivated by allergen re-exposure. In support of this, allergen-specific IgG 1 + memory B cells have been detected in mice at least 9 months after intragastric allergen sensitization [ [20] , which has been shown to be a reservoir of high-affinity IgE in a model of Nippostrongylus brasiliensis infection [21••] . In humans, B cell repertoire studies with peripheral blood mononuclear cells (PBMCs) of allergic individuals have also supported the important role of sequential class-switching in IgE immunity [22•] . Additionally, it has been shown that the majority of IgE + plasma cells (PCs) formed in tonsillar B cell cultures stimulated with IL-4 and anti-CD40 developed through sequential class-switching from IgG 1 [23] .
Collectively, this body of literature indicates that the allergen-specific memory B cell compartment generated in Th2 responses is largely populated by IgG 1 + B cells. Given the critical role of IL-4 in IgE class-switching [9, 24, 25] , IL-4Rα blockade during AIT may prevent the generation of IgEproducing PCs, perhaps empowering an IgG and IgA response. In this context, elucidating the cellular and molecular mechanisms that drive IgG class-switching during AIT towards a protective (IgG4, IgA) rather than a pathogenic (IgE) isotype is of the utmost clinical importance.
The Intriguing IgG Response
Humoral IgG immunity is intriguing because of its complexity. In mice, it encompasses 4 subclasses (IgG 1 , IgG 2a , IgG 2b , and IgG 3 ) that bind with variant affinities to both inflammatory (FcɣRI, FcɣRIII, FcɣRIV) and inhibitory (FcɣRIIb) receptors of heterogeneous expression [26] . For example, murine IgG 1 is capable of driving anaphylaxis despite having higher affinity towards FcɣRIIb. This is partly because the stimulatory signaling of the Fcɣ RIII-associated immunoreceptor tyrosine-based activation motif (ITAM) can dominate the inhibitory effects of the FcɣRIIb-associated immunoreceptor tyrosine-based inhibitory motif [26] . Consequently, every IgG subclass (except for IgG 3 ) can induce murine anaphylaxis via FcɣRIII [27] . Furthermore, as aforementioned, IgG 1 + B cell immunity has been shown to precede IgE responses in a mouse model of skin sensitization to foods [20] , and pre-atopic related IgG responses have been reported in birch-sensitized children [28, 29] . In contrast, a serum increase of allergen-specific IgG 4 occurs during AIT [10] and murine models have investigated the protective role of allergen-specific IgG antibodies [30, 31, 32 
Finkelman's group elegantly ascertained two protective mechanisms of humoral IgG in models of active and passive immunization with goat anti-mouse IgD and TNP [30] . One is based solely on the ability of IgG antibodies to bind allergen, thus preventing allergen-IgE cross-linking; the second requires FcɣRIIb cross-linking, which prevents mast cell degranulation [30] . These mechanisms are not mutually exclusive and may be synergistic. Novel work by Zha et al. showed in mice that the affinity of IgG governed their functionality insofar that high-affinity IgG exerted both blocking and inhibitory activity, while low affinity IgG only acted via FcɣRIIb [34•] . The relevance of the IgG-FcɣRIIb axis in murine models was shown by Oettgen's group using food allergyprone mice (IL4raF709) which were sensitized to egg ovalbumin (OVA) intragastrically along with cholera toxin. Following desensitization, these mice developed allergenspecific IgG that prevented bone marrow-derived mast cell degranulation ex vivo in an FcɣRIIb-dependant manner [31] . In a similar murine model, the same group reported that administration of OVA-specific IgG together with OVA promoted desensitization via FcɣRIIb [35••] . Moreover, Ohsaki et al. demonstrated in a murine model of epicutaneous sensitization that the FcRn-dependent transfer of OVA-IgG immune complexes from allergic mothers induced T-regulatory cells in their offspring, which prevented the development of allergy [36] . This process was mediated via FcγRIIb signaling on CD11c+ dendritic cells (DCs). The impact of allergenspecific IgG on other immune subsets expressing FcɣRIIb has been largely unexplored. For example, memory B cells express FcɣRIIb and can be modulated through IgG signaling. This mechanism regulates B cell immunity as FcɣRII-deficient mice develop self-reactive germinal center B cells and PCs [37] . Thus, it stands to reason that allergen-specific IgG may also modulate allergen-specific B cell responses through FcɣRIIb. Altogether, these findings suggest that allergenspecific IgG administration in AIT may block mast cell degranulation and downstream secretion of IL-4, perhaps aiding a shift to a T-reg/Th2 balance as it has been observed in patients that outgrow allergy [38] .
The concept of passive immunization via exogenous administration of allergen-specific IgG has been explored in a murine model of passive cutaneous anaphylaxis to Fel d 1, a major allergen from cat dander [39••] . A single dose of two monoclonal, high-affinity IgG 4 antibodies specific to Fel d 1 was sufficient to prevent clinical reactivity in a proof of concept randomized clinical trial. Cat allergic patients underwent serial nasal allergen challenges with cat hair extract with significant benefit in treated subjects, which continued even as serum concentrations of the therapeutic antibodies waned [39••] . This novel study highlights the therapeutic value of IgG in the context of AIT. More importantly, it implies that the persistence of high-affinity, strong neutralizing antibodies can provide clinically effective protection at low serum concentrations. While the de novo IgG 4 response induced during AIT declines after cessation of AIT [39••] , the persistence of blocking antibodies correlates with clinical tolerance [40] . Therefore, the induction of a sustained, anti-inflammatory, neutralizing IgG response may control the symptoms of allergic disease and encourage the development of tolerance. On this matter, the growing expertise of biopharmaceutical industries in the generation of biologics, including allergen-specific humanized antibodies, may expedite the clinical use of exogenous IgG for AIT [39••, 41] .
The optimal development of this therapeutic arm may require the establishment of long-lived IgG + PCs, and memory B cell populations that do not class-switch to IgE on allergen exposure but replenish the anti-inflammatory IgG + PCs. Yet, these biological processes are poorly understood, particularly in allergic diseases [9] . State-of-the-art techniques to identify, isolate and characterize allergen-specific B cells have provided new insights into memory B cell responses. Using an allergen-specific tetramer, early and transient induction of allergen-specific, class-switched memory B cells during peanut oral AIT has been reported and confirmed [42••] . These peanut-specific memory B cells exhibited high-affinity BCRs that were highly mutated. Previous comparison of pre-and post-oral peanut AIT sera using microarrays have suggested that allergen-specific IgG antibodies with new specificities can develop in AIT [43] . In agreement with this, a study of allergenspecific IgG lineages demonstrated clonal evolution during peanut AIT [44•] . Together, these data suggest that AIT not only contributes to the effector antibody repertoire, but that it may also mediate the replenishing and tuning of the allergen-specific memory B cell repertoire in allergic individuals.
While tremendous strides in deciphering fundamental contributions of humoral IgG have been made, additional avenues remain ripe for exploration. The narrow focus on allergenspecific IgG 4 in AIT has neglected the fact that other subclasses in human allergic disease may contribute to the overall blocking and inhibitory IgG response. Previously, in vitro assays using IgG subclasses other than IgG 4 have shown effector cell suppression through blocking IgE-allergen binding [45] . Immunoregulatory functions of IgG and IgA induced by AIT are only beginning to be explored [46] . Other sources of variability in antibodies, such as Fc modification by glycosylation, recently shown to alter IgE binding to its high-affinity receptor [47•] , have likewise been unexplored. A more comprehensive analysis of the multiple sources of variability and their mechanistic contribution to tolerance in AIT may pave the path for new innovations in treatment for food allergy.
Mucosal and Systemic IgA: Necessary Players in AIT
The most common habitat of IgA is the mucosal epithelium, where it is secreted in dimeric form [48] . On the other hand, the monomeric form of IgA prevails in blood (5:1, monomeric:dimeric ratio) [49] as the second most abundant class after IgG and, like its mucosal counterpart, it exerts primarily a blocking function [50] [51] [52] . A number of epidemiological studies sought an association between the lack of IgA (in patients with hypogammaglobulinemia) and the development of allergic diseases, but the data generated were inconclusive [53, 54] . Nevertheless, several lines of evidence point towards a regulatory role of IgA responses in allergy. As an example, high intestinal IgA is correlated with reduced risk of IgE-associated allergic diseases [55] , and a retrospective study has recently shown that aberrant mucosal IgA responses against gut microbiota in infancy predate the development of allergic diseases [56] .
The protective role of IgA in allergy extends beyond allergic sensitization. Indeed, regulation of the B cell compartment in response to AIT includes increases in serum and mucosal IgA in mice [57] [58] [59] [60] . In addition, serum levels of allergenspecific IgA have been found to increase in oral and sublingual AIT for food allergy [10, 42••, 61] as well as environmental AIT [62, 63] . While secreted IgA has traditionally attracted more interest because of its dominant role at mucosal sites [64] , Finkelman's group demonstrated the ability of circulatory IgA to prevent IgE-mediated anaphylaxis in murine models of active (OVA plus alum) and passive (TNP-specific IgE) immunization [65] . Furthermore, salivary allergen-specific IgA has been identified as a highly effective biomarker in peanut sublingual AIT in humans, as it closely correlated with the degree of tolerance post-AIT. This also supports a protective role for local IgA blocking of allergen at a mucosal level in AIT. Hence, secretory IgA offers a first wave of protection by blocking allergens absorbed mucosally, as the lack of IgA increases intestinal permeability [65] . Upon systemic access of the allergen, which is required for IgE-mediated anaphylaxis [65] , allergen-specific IgA (together with allergen-specific IgG) constitutes the last bastion. Subsequent studies [45, [66] [67] [68] have confirmed these findings and outlined additional roles for IgA which, besides its blocking ability, can mediate cellular effects through various receptors [69] . The interaction of IgA with its natural receptor (FcαRI, CD89), which is expressed by myeloid cells, triggers FcɣR-ITAM-driven cellular responses [70] . Interestingly, if the aggregation of the receptor is not sustained, the ITAM changes conformation, recruits the Src homology region 2 domaincontaining phosphatase-1 (SHP-1), and induces inhibitory signals. For instance, the administration of A77 Fab fragments, which monovalently target FcαRI, suppressed clinical manifestations of allergic asthma in FcαRI transgenic mice [71] . Additionally, a recent study explored the ability of IgA to modulate DCs from patients with allergic rhinitis (Der p 1 sensitized) upon allergen stimulation. IgA induced immunosuppressive effects on T cells that were mediated through the notch ligand Delta-like 4 (DLL4) on DCs [72] . Conversely, if the aggregation of FcαRI is sustained, as it may happen with multimeric ligands, ITAM binds Syk [71] and causes an inflammatory response [73, 74] . Even so, under physiological conditions, FcαRI most frequently combats inflammation [49, 69, 70] .
Secretory IgA can also interact with DCs through the specific intercellular adhesion molecule (ICAM)-3 grabbing nonintegrin receptor 1 (SIGNR1), which is the mouse homolog of human DC-SIGN. This interaction is specific of structural domains present in secretory IgA, but not dimeric IgA or the secretory component, and has been shown to prevent bone marrow-derived DC maturation and secretion of proinflammatory cytokines upon TLR stimulation. This facilitated the acquisition of a tolerogenic phenotype characterized by IL-10 production and promoted the generation of OTII CD4 + T-regs in culture [75] .
To summarize, the generation of allergen-specific IgA in AIT may exert several protective roles that include allergen blockade, thereby preventing IgE-mediated reactions and associated pathology as well as dampening inflammatory responses through FcαRI signaling and the induction of a DC-T-regulatory response. In this context, a better understanding of the mechanisms underlying allergen-specific IgA responses in AIT is required for the development of therapeutic strategies that fully exploit the tolerogenic potential of IgA.
B Cells as Regulatory Cells in AIT
B-regs, which are comprised of a heterogeneous group of B cells, and certain populations of PCs [76, 77•] , are defined by their immunosuppressive properties and have been described in mice and humans [38] . The different subsets of B-regs have been extensively reviewed by van de Veen et al. [78] . Although thus far no B-reg transcription factor has been identified, a commonality of them that is central to their immunoregulatory potential is their ability to produce IL-10 [79, 80] .
A pivotal function of IL-10 [81] and IL-10-producing Bregs [82] in AIT is the development of the IgG 4 response. Using peripheral blood from chronically bee venom exposed beekeepers with natural tolerance as well as subjects on subcutaneous venom AIT with acquired tolerance, Akdis' group identified and characterized phospholipase A 2-specific Bregs [82] . These allergen-specific B-regs had increased production of IL-10 and IgG 4 expression, and a majority of Bregs exhibited an IgG 4 + memory phenotype. These findings indicate that B-regs may serve as a reservoir of the humoral IgG 4 arm induced by chronic allergen exposure, naturally or through AIT, which is a mechanism of tolerance [82] . More recently, PLA2-specific IgG 4 + memory B cells were found to expand and express higher levels of CCR5 after AIT [83•] , which may allow them to migrate to inflammatory sites to provide local immunosuppression.
Experimental models have served to decipher immunomodulatory mechanisms of B-regs in allergy (beyond IL-10 production) [78, 84] . B-regs can secrete other soluble molecules with regulatory roles (TGF-β, IL-35, thrombospondin 1 (TSP-1), IDO, etc.) but can also express surface bound molecules that enable cellular interactions of immunosuppressive nature (e.g., PD-1, FASL, CD73, CD9, CD1d) [80, 85, 86, 87•, 88•, 89••] (Fig. 1) . As an example, TGF-β-producing Bregs (CD5 + CD1d high ) from hilar lymph nodes were reported in a model of OVA-induced asthma in which allergic airway disease was followed by development of tolerance. These suppressive B-regs expanded in tolerant mice, induced CD4 T-regs and prevented airway eosinophilia upon adoptive + B-regs that produced TGF-β in response to αvβ6 and BCR-cross linking with anti-IgM [91] . The enteric production of CX3CL1, the natural ligand of CX3CR1 + [92] , may direct the recruitment of these cells into the gut. Indeed, the adoptive transfer of these cells ameliorated local production of allergen-specific IgE, Th2 cytokines and mMCP-1 in a cholera toxin model of intragastric sensitization to OVA [91] . In a closely related system, Zhang et al. found that CD35 + B cells expanded in the gut of OVA allergic mice following oral AIT. These cells exhibited expression of TSP-1 [93] , which enhances activation of TGF-β [94] . Given the central role of TGF-β in IgA class-switching [95] , the presence of CD35 + Bregs expressing TSP-1 and/or TGF-β producing CX3CR1 + Bregs in the intestine may promote mucosal IgA immunity during AIT.
Concluding Remarks
Since Robert Cooke's seminal discovery in 1955 that ragweed AIT induced IgE blocking IgG [96] , we have appreciated the central and multifaceted role of antibodies as effector molecules in AIT. Since then, we have gained a nuanced understanding of how different allergen-specific antibody isotypes may influence cellular aspects of allergen-specific tolerance in AIT, which are summarized in Fig. 1 . Allergen-specific IgG has been shown to have synergistic abilities by sequestering antigen from IgE on effector cells, but also modulating cellular activation through Fc receptors. Likewise, allergen-specific IgA has moved beyond its role in sequestering antigen at the mucosal level, but to also influence antigen-sampling and modulate other immune cell subsets. Moreover, B cells have been recognized to have a regulatory role in AIT, through IL-10 secretion and production of protective antibodies, but it is also supported by a plethora of complementary mechanisms (Fig. 2) .
Throughout this review, we have discussed novel regulatory mechanisms of B cell immunity in AIT. These advances mark a new chapter in our fundamental understanding of B cell biology and have clear implications in allergic disease. The growing knowledge on the protective cellular and humoral mechanisms in AIT is paving the way for the development of novel therapeutic strategies in allergy and might be exploited for the treatment of other immune-tolerance diseases.
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